<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Analgesics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i56.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i56.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i56.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i989.htm" title="Previous: Anakinra">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i58.htm" title="Next: Nefopam">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i56">Analgesics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Analgesics</b>
          has no specific interaction information.
        </p><p><b>Nefopam</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td>side-effects possibly increased when  nefopam given with tricyclics </td><td></td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  nefopam given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>manufacturer of  nefopam advises avoid concomitant use with MAOIs </b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr></tbody></table><p><b>Aspirin</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>
























<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>increased risk of toxicity when high-dose  aspirin given with acetazolamide </b></td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>excretion of  aspirin increased by alkaline urine due to some antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>increased risk of bleeding when  aspirin given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td>increased risk of bleeding when  aspirin given with clopidogrel </td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>increased risk of gastro-intestinal bleeding and ulceration when  aspirin given with corticosteroids , also corticosteroids reduce plasma concentration of salicylate</td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b>increased risk of bleeding when  aspirin given with coumarins (due to antiplatelet effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td>possible increased risk of toxicity when high-dose  aspirin given with loop diuretics (also possible reduced effect of loop diuretics)</td><td></td></tr><tr><td><a href="41001i224.htm">Heparins</a></td><td class="cBV"><b> aspirin enhances anticoagulant effect of heparins </b></td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td>antiplatelet effect of  aspirin possibly reduced by ibuprofen </td><td></td></tr><tr><td><a href="41001i1015.htm">Iloprost</a></td><td>increased risk of bleeding when  aspirin given with iloprost </td><td></td></tr><tr><td><a href="41001i14.htm">Kaolin</a></td><td>absorption of  aspirin possibly reduced by kaolin </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> aspirin reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>rate of absorption of  aspirin increased by metoclopramide (enhanced effect)</td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>avoid concomitant use of  aspirin with NSAIDs (increased side-effects)</b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b>increased risk of bleeding when  aspirin given with phenindione (due to antiplatelet effect)</b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> aspirin enhances effects of phenytoin </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td> aspirin antagonises effects of probenecid </td><td></td></tr><tr><td><a href="41001i549.htm">Spironolactone</a></td><td> aspirin antagonises diuretic effect of spironolactone </td><td></td></tr><tr><td><a href="41001i689.htm">Sulfinpyrazone</a></td><td> aspirin antagonises effects of sulfinpyrazone </td><td></td></tr><tr><td><a href="41001i42.htm">Thiopental</a></td><td> aspirin possibly enhances effects of thiopental </td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> aspirin enhances effects of valproate </td><td></td></tr><tr><td><a href="41001i1223.htm">Varicella-zoster Vaccine</a></td><td>possible risk of Reyes syndrome when  aspirin given with varicella-zoster vaccine—manufacturers advise avoid aspirin for 6 weeks after giving varicella-zoster vaccine</td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>increased risk of bleeding when  aspirin given with venlafaxine </b></td><td></td></tr><tr><td><a href="41001i859.htm">Zafirlukast</a></td><td> aspirin increases plasma concentration of zafirlukast </td><td></td></tr></tbody></table><p><b>Paracetamol</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i993.htm">Busulfan</a></td><td> paracetamol possibly inhibits metabolism of <i>intravenous</i> busulfan (manufacturer of <i>intravenous</i> busulfan advises caution within 72 hours of paracetamol)</td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>metabolism of  paracetamol possibly accelerated by carbamazepine (also isolated reports of hepatotoxicity)</td><td></td></tr><tr><td><a href="41001i592.htm">Colestyramine</a></td><td>absorption of  paracetamol reduced by colestyramine </td><td>Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td>prolonged regular use of  paracetamol possibly enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td>caution with  paracetamol advised by manufacturer of imatinib </td><td></td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>rate of absorption of  paracetamol increased by metoclopramide </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>metabolism of  paracetamol possibly accelerated by phenobarbital (also isolated reports of hepatotoxicity)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>metabolism of  paracetamol possibly accelerated by phenytoin (also isolated reports of hepatotoxicity)</td><td></td></tr></tbody></table><p><b>NSAIDs</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><div><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>













































<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td>increased risk of renal impairment when  NSAIDs given with ACE inhibitors , also hypotensive effect antagonised</td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td> NSAIDs antagonise hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td> NSAIDs possibly antagonise hypotensive effect of aliskiren </td><td></td></tr><tr><td><a href="41001i26.htm">Alpha-blockers</a></td><td> NSAIDs antagonise hypotensive effect of alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>increased risk of renal impairment when  NSAIDs given with angiotensin-II receptor antagonists , also hypotensive effect antagonised</td><td></td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>increased risk of bleeding when  NSAIDs given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td class="cBV"><b>avoid concomitant use of  NSAIDs with aspirin (increased side-effects)</b></td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td> NSAIDs possibly reduce excretion of baclofen (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td> NSAIDs antagonise hypotensive effect of beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td> NSAIDs antagonise hypotensive effect of calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td> NSAIDs possibly increase plasma concentration of cardiac glycosides , also possible exacerbation of heart failure and reduction of renal function</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  NSAIDs given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td> NSAIDs antagonise hypotensive effect of clonidine </td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td>increased risk of bleeding when  NSAIDs given with clopidogrel </td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>increased risk of gastro-intestinal bleeding and ulceration when  NSAIDs given with corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> NSAIDs possibly enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b>possible increased risk of bleeding when  NSAIDs given with dabigatran etexilate </b></td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td> NSAIDs antagonise hypotensive effect of diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>risk of nephrotoxicity of  NSAIDs increased by diuretics , also antagonism of diuretic effect</td><td></td></tr><tr><td><a href="41001i544.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td>possible increased risk of hyperkalaemia when  NSAIDs given with potassium-sparing diuretics and aldosterone antagonists </td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>increased risk of bleeding when  NSAIDs given with erlotinib </b></td><td></td></tr><tr><td><a href="41001i224.htm">Heparins</a></td><td>possible increased risk of bleeding when  NSAIDs given with heparins </td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td> NSAIDs antagonise hypotensive effect of hydralazine </td><td></td></tr><tr><td><a href="41001i1015.htm">Iloprost</a></td><td>increased risk of bleeding when  NSAIDs given with iloprost </td><td></td></tr><tr><td><a href="41001i72.htm">Ketorolac</a></td><td class="cBV"><b>avoid concomitant use of  NSAIDs with ketorolac (increased side-effects and haemorrhage)</b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b> NSAIDs reduce excretion of lithium (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> NSAIDs probably reduce excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td> NSAIDs antagonise hypotensive effect of methyldopa </td><td></td></tr><tr><td><a href="41001i1173.htm">Mifamurtide</a></td><td>avoidance of high doses of  NSAIDs advised by manufacturer of mifamurtide </td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td> NSAIDs antagonise hypotensive effect of minoxidil </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td> NSAIDs antagonise hypotensive effect of moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td> NSAIDs antagonise hypotensive effect of nitrates </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>avoid concomitant use of  NSAIDs with NSAIDs (increased side-effects)</b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i658.htm">Penicillamine</a></td><td>possible increased risk of nephrotoxicity when  NSAIDs given with penicillamine </td><td></td></tr><tr><td><a href="41001i826.htm">Pentoxifylline</a></td><td>possible increased risk of bleeding when  NSAIDs given with pentoxifylline </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> NSAIDs possibly enhance anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i1110.htm">Potassium Canrenoate</a></td><td> NSAIDs possibly antagonise diuretic effect of potassium canrenoate </td><td></td></tr><tr><td><a href="41001i1146.htm">Prasugrel</a></td><td>possible increased risk of bleeding when  NSAIDs given with prasugrel </td><td></td></tr><tr><td><a href="41001i193.htm">Quinolones</a></td><td class="cBV"><b>possible increased risk of convulsions when  NSAIDs given with quinolones </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  NSAIDs possibly increased by ritonavir </td><td></td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td> NSAIDs antagonise hypotensive effect of sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> NSAIDs possibly enhance effects of sulfonylureas </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td>possible increased risk of nephrotoxicity when  NSAIDs given with tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>increased risk of bleeding when  NSAIDs given with venlafaxine </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td>increased risk of haematological toxicity when  NSAIDs given with zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Dexibuprofen</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Parecoxib</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  parecoxib increased by fluconazole (reduce dose of parecoxib)</td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr></tbody></table><p><b>Etoricoxib</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td> etoricoxib increases plasma concentration of ethinylestradiol </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  etoricoxib reduced by rifampicin </td><td></td></tr></tbody></table><p><b>Aceclofenac</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Acemetacin</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Celecoxib</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  celecoxib increased by fluconazole (halve dose of celecoxib)</td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  celecoxib reduced by rifampicin </td><td></td></tr></tbody></table><p><b>Dexketoprofen</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  dexketoprofen reduced by probenecid (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Diclofenac</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i219.htm">Anticoagulants</a></td><td class="cBV"><b>increased risk of haemorrhage when <i>intravenous</i>  diclofenac given with anticoagulants (avoid concomitant use, including low-dose heparins)</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  diclofenac increased by ciclosporin (halve dose of diclofenac)</b></td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> diclofenac reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  diclofenac reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>plasma concentration of  diclofenac increased by voriconazole </td><td></td></tr></tbody></table><p><b>Etodolac</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Fenoprofen</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Flurbiprofen</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  flurbiprofen increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr></tbody></table><p><b>Ibuprofen</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i361.htm">Aspirin</a></td><td> ibuprofen possibly reduces antiplatelet effect of aspirin </td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td> ibuprofen reduces excretion of baclofen (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  ibuprofen increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> ibuprofen reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ibuprofen given with tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>plasma concentration of  ibuprofen increased by voriconazole </td><td></td></tr></tbody></table><p><b>Indometacin</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i129.htm">Amikacin</a></td><td> indometacin possibly increases plasma concentration of amikacin in neonates</td><td></td></tr><tr><td><a href="41001i795.htm">Desmopressin</a></td><td> indometacin enhances effects of desmopressin </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td> indometacin antagonises effects of diuretics </td><td></td></tr><tr><td><a href="41001i544.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td>increased risk of hyperkalaemia when  indometacin given with potassium-sparing diuretics and aldosterone antagonists </td><td></td></tr><tr><td><a href="41001i131.htm">Gentamicin</a></td><td> indometacin possibly increases plasma concentration of gentamicin in neonates</td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td>possible severe drowsiness when  indometacin given with haloperidol </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> indometacin reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  indometacin reduced by probenecid (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i546.htm">Triamterene</a></td><td class="cBV"><b>occasional reports of reduced renal function when  indometacin given with triamterene—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Ketoprofen</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> ketoprofen reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  ketoprofen reduced by probenecid (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Ketorolac</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i219.htm">Anticoagulants</a></td><td class="cBV"><b>increased risk of haemorrhage when  ketorolac given with anticoagulants (avoid concomitant use, including low-dose heparins)</b></td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td> ketorolac antagonises effects of diuretics </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b> ketorolac reduces excretion of lithium (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>avoid concomitant use of  ketorolac with NSAIDs (increased side-effects and haemorrhage)</b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i826.htm">Pentoxifylline</a></td><td class="cBV"><b>increased risk of bleeding  when  ketorolac given with pentoxifylline (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  ketorolac reduced by probenecid (increased plasma concentration)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Mefenamic Acid</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Meloxicam</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i592.htm">Colestyramine</a></td><td>excretion of  meloxicam increased by colestyramine </td><td>Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> meloxicam reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr></tbody></table><p><b>Nabumetone</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Naproxen</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> naproxen reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  naproxen reduced by probenecid (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Piroxicam</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  piroxicam increased by ritonavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Sulindac</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i1130.htm">Dimethyl sulfoxide</a></td><td class="cBV"><b>avoid concomitant use of  sulindac with dimethyl sulfoxide </b></td><td></td></tr></tbody></table><p><b>Tenoxicam</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Tiaprofenic Acid</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Tolfenamic Acid</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Opioid Analgesics</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i20.htm">Alcohol</a></td><td>enhanced hypotensive and sedative effects when  opioid analgesics given with alcohol </td><td></td></tr><tr><td><a href="41001i40.htm">Anaesthetics, General (intravenous)</a></td><td> opioid analgesics possibly enhance effects of intravenous general anaesthetics </td><td></td></tr><tr><td><a href="41001i46.htm">Anaesthetics, General (volatile liquids)</a></td><td> opioid analgesics possibly enhance effects of volatile liquid general anaesthetics </td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td>sedative effects possibly increased when  opioid analgesics given with tricyclics </td><td></td></tr><tr><td><a href="41001i311.htm">Antihistamines, Sedating</a></td><td class="cBV"><b>sedative effects possibly increased when  opioid analgesics given with sedating antihistamines </b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>enhanced hypotensive and sedative effects when  opioid analgesics given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  opioid analgesics given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  opioid analgesics inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td> opioid analgesics antagonise effects of domperidone on gastro-intestinal activity</td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  opioid analgesics given with MAOIs—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td> opioid analgesics antagonise effects of metoclopramide on gastro-intestinal activity</td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  opioid analgesics given with moclobemide—manufacturer of moclobemide advises consider reducing dose of opioid analgesics</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>avoidance of  opioid analgesics advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i1067.htm">Sodium Oxybate</a></td><td class="cBV"><b> opioid analgesics enhance effects of sodium oxybate (avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Tapentadol</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Alfentanil</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i468.htm">Diltiazem</a></td><td>metabolism of  alfentanil inhibited by diltiazem (risk of prolonged or delayed respiratory depression)</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  alfentanil increased by erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>metabolism of  alfentanil inhibited by fluconazole (risk of prolonged or delayed respiratory depression)</td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>metabolism of  alfentanil possibly inhibited by itraconazole </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  alfentanil accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  alfentanil increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  alfentanil given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  alfentanil increased by voriconazole (consider reducing dose of alfentanil)</b></td><td></td></tr></tbody></table><p><b>Buprenorphine</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>metabolism of  buprenorphine inhibited by ketoconazole (reduce dose of buprenorphine)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  buprenorphine possibly increased by ritonavir </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td> buprenorphine possibly reduces plasma concentration of tipranavir </td><td></td></tr></tbody></table><p><b>Codeine</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>possible increased risk of antimuscarinic side-effects when  codeine given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  codeine accelerated by rifampicin (reduced effect)</td><td></td></tr></tbody></table><p><b>Dextromethorphan</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i942.htm">Memantine</a></td><td class="cBV"><b>increased risk of CNS toxicity when  dextromethorphan given with memantine (manufacturer of memantine advises avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  dextromethorphan given with moclobemide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>avoid concomitant use of  dextromethorphan with rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr></tbody></table><p><b>Dextropropoxyphene</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> dextropropoxyphene enhances effects of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  dextropropoxyphene increased by ritonavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Diamorphine</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Dihydrocodeine</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Diphenoxylate</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Dipipanone</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Fentanyl</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>plasma concentration of  fentanyl possibly increased by triazoles </b></td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td>increased sedative effect when  fentanyl given with baclofen </td><td></td></tr><tr><td><a href="41001i43.htm">Etomidate</a></td><td> fentanyl inhibits metabolism of etomidate (consider reducing dose of etomidate)</td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td> fentanyl possibly inhibits metabolism of midazolam </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  fentanyl accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  fentanyl increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  fentanyl given with saquinavir—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Hydromorphone</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Meptazinol</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Methadone</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>























<tr><td><a href="41001i907.htm">Abacavir</a></td><td>plasma concentration of  methadone possibly reduced by abacavir </td><td></td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with antipsychotics that prolong the QT interval</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  methadone reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i397.htm">Didanosine</a></td><td> methadone possibly reduces plasma concentration of didanosine </td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  methadone reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>plasma concentration of  methadone possibly increased by fluoxetine </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of  methadone possibly increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>plasma concentration of  methadone reduced by fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  methadone reduced by nelfinavir </td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  methadone possibly reduced by nevirapine </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td>plasma concentration of  methadone possibly increased by paroxetine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  methadone reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>metabolism of  methadone accelerated by phenytoin (reduced effect and risk of withdrawal effects)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  methadone accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  methadone reduced by ritonavir </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td>plasma concentration of  methadone possibly increased by sertraline </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  methadone possibly reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>caution with  methadone advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  methadone increased by voriconazole (consider reducing dose of methadone)</b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td> methadone possibly increases plasma concentration of zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Morphine</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i617.htm">Baclofen</a></td><td>increased sedative effect when  morphine given with baclofen </td><td></td></tr><tr><td><a href="41001i447.htm">Esmolol</a></td><td> morphine possibly increases plasma concentration of esmolol </td><td></td></tr><tr><td><a href="41001i282.htm">Gabapentin</a></td><td> morphine increases bioavailability of gabapentin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  morphine accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  morphine possibly reduced by ritonavir </td><td></td></tr></tbody></table><p><b>Oxycodone</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  oxycodone possibly accelerated by rifampicin </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td>metabolism of  oxycodone inhibited by telithromycin </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  oxycodone increased by voriconazole </b></td><td></td></tr></tbody></table><p><b>Papaveretum</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Pentazocine</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Pethidine</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  pethidine given with duloxetine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>CNS excitation or depression (hypertension or hypotension) when  pethidine given with MAOIs—avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  pethidine given with moclobemide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>risk of CNS toxicity when  pethidine given with rasagiline (avoid pethidine for 2 weeks after rasagiline)</b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  pethidine reduced by ritonavir , but plasma concentration of toxic pethidine metabolite increased (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>hyperpyrexia and CNS toxicity reported when  pethidine given with selegiline (avoid concomitant use)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr></tbody></table><p><b>Phenazocine</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Remifentanil</b> belongs to
      <b>Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Tramadol</b> belongs to
      <b>Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tramadol given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tramadol given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>increased risk of convulsions when  tramadol given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td>possible increased risk of convulsions when  tramadol given with atomoxetine </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>effects of  tramadol reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> tramadol enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  tramadol given with duloxetine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>possible increased serotonergic effects and increased risk of convulsions when  tramadol given with MAOIs—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  tramadol given with mirtazapine </td><td></td></tr><tr><td><a href="41001i1045.htm">Ondansetron</a></td><td>effects of  tramadol possibly antagonised by ondansetron </td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>possible increased serotonergic effects when  tramadol given with venlafaxine </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i58.htm" title="Nefopam">Nefopam</a></li><li><a href="41001i361.htm" title="Aspirin">Aspirin</a></li><li><a href="41001i59.htm" title="Paracetamol">Paracetamol</a></li><li id="_41001i60"><a href="41001i60.htm" title="NSAIDs">NSAIDs</a></li><li id="_41001i85"><a href="41001i85.htm" title="Opioid Analgesics">Opioid Analgesics</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i989.htm">Previous: Anakinra</a> | <a class="top" href="41001i56.htm#">Top</a> | <a accesskey="]" href="41001i58.htm">Next: Nefopam</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>